Abstract:Objective To explore the clinical value of chemotherapy in the treatment of thymic tumors. Methods 739 patients with Masaoka stage Ⅲ/Ⅳa or the chemotherapy cases between March 1994 and December 2012 were retrospectively analyzed based on the Chinese Alliance of Research for Thymomas(ChART)database. The clinical value of different modes of chemotherapy was estimated, the survival curves were drawn according to different subgroups, and the factors affecting the prognosis were analyzed. Results The Masaoka-Koga stage, completion of resection and pathological type were the main influencing factors of long-term survival. The efficiency of primary chemotherapy was 50.8%(30/59), and the objective response rate was 11.9%(7/59). The primary chemotherapy improved complete resection rate from 66.6%(397/596) to 72.9%(43/59). The 5-year survival and 10-year survival of non-postoperative chemotherapy group and postoperative chemotherapy group in patients with Masaoka-Koga Ⅲ/Ⅳ thymic carcinoma were 71.0% vs 66.6% and 53.5% vs 42.6%, respectively(χ2=0.003, P=0.953). The 5-year survival of non-postoperative chemotherapy group and postoperative chemotherapy group in patients with stage IV thymic tumor were 85.7% and 76.1%, respectively(χ2=0.030, P=0.862). The 5-year survival and 10-year survival of non-postoperative chemotherapy group and postoperative chemotherapy group in patients with stage Ⅲ thymoma were 92.1% vs 65.0% and 88.1% vs 59.6%, respectively(χ2=13.294, P=0.000). For the patients with complete resected thymoma in stage Ⅲ and Ⅳ, the 5-year survival of patients without and with postoperative chemotherapy were 92.8% and 67.2%, respectively(χ2=10.856, P=0.001). Conclusions Primary chemotherapy can slightly improve the complete resection rate, while postoperative chemotherapy cannot improve the long-term outcomes of thymic tumors. Postoperative chemotherapy does no good to the MasaokaⅢ thymoma and thymic tumor with localized advanced complete resection. Key words: Thymic tumor; Chemotherapy; Surgery; Prognosis

Clinical Value of Chemotherapy for Thymictumors: a Retrospective Analysis Based on the Results of the Chinese Alliance of Research for Thymomas Database